Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics said on Tuesday its experimental drug to treat obesity helped achieve "significant" weight loss in a mid-stage study.

Viking Therapeutics' weight-loss drug succeeds in mid-stage study

Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo Up to 13.1% Placebo-Adjusted Mean Weight Loss (14.7% From Baseline) Observed After 13 Weeks of Treatment; No Plateau Observed  VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 95% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO , Feb. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's Phase 2 clinical trial of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the potential treatment of various metabolic disorders such as obesity.

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

Viking Therapeutics (VKTX) stock price has silently emerged as one of the best-performing companies in Wall Street this year. It jumped by over 14% on Friday and is up by 1.20% in the pre-market session as investors predict that it could be acquired.

What's going on with the Viking Therapeutics (VKTX) stock price?

Arcellx

ADC Therapeutics

Following a hot year of M&A with biotech stocks, we'll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between now and 2028, pharmaceutical giants stand to lose billions in revenue as blockbuster drug patents expire.

The 3 Biotech Stocks That Could Make Your February Unforgettable

Amgen

AstraZeneca

DexCom

Eli Lilly

Novo Nordisk

Pfizer

It is entirely fair to state that weight loss treatments have massive transformational power. US FDA approval of weight loss medicines could help shrink millions of waistlines.

7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution

Viking Therapeutics Inc.'s stock soared 17% to a record high on Thursday, after the company said it expects data from early and mid-stage trials of its weight-loss drug as soon as the first quarter, moving the timeline up from the first half.

Viking Therapeutics may offer investors a cheap entry to the weight-loss drug craze

Intellia Therapeutics

With patience, some of the most undervalued biotech stocks can create massive wealth. Look at ACADIA Pharmaceuticals (NASDAQ: ACAD ), for example.

The 3 Most Undervalued Biotech Stocks to Buy in February 2024

Viking Therapeutics moved up its timeline for an Eli Lilly-rivaling obesity treatment on Thursday, leading VKTX stock to a record high.

Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug

Viking Therapeutics, Inc. (VKTX) Q4 2024 Earnings Call Transcript

Conference call scheduled for 4:30 p.m. ET today Results for Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Expected in 1Q24 Histology Results for Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis Expected in 1H24 Results for Phase 1 Trial of Oral VK2735 Expected in 1Q24 Strong Year-End Cash Position of $362 Million SAN DIEGO , Feb. 7, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided an update on its clinical pipeline and other corporate developments.

Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

United Rentals

V.F.

Verizon

Vizsla Silver Corp

Westamerica Bancorp

Walgreens

W. P. Carey

MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income. Part 9 of this series includes Verizon Communications, V.F. Corp, Vizsla Silver, Walgreens Boots Alliance and W. P. Carey, among others.

MoneyShow's Best Investment Ideas For 2024: Part 9

Alkermes

Ardelyx

The quest for prime biotech stocks for gains will always be relevant. Moreover, 2024 promises a surge in technology and science, positioning biotech firms at the forefront of novel medical breakthroughs.

The 3 Best Biotech Stocks to Invest in for Big Gains in 2024

Conference Call Scheduled for Wednesday, February 7 at 4:30 p.m. Eastern Time SAN DIEGO , Jan. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2023 after the market close on Wednesday, February 7, 2024.

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024

Madrigal Pharmaceuticals

Novo Nordisk has been a great investment due to its drugs for diabetes and obesity. Madrigal Pharmaceuticals has big plans for treating a serious liver disease known as NASH.

2 Rising Biotechs That Could Become the Next Novo Nordisk

Mersana Therapeutics

Biotech stocks are some of the most exciting opportunities on the market.  Find the right ones with substantial catalysts and make a fortune.

3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024

Madrigal Pharmaceuticals is inching closer to an important approval. Viking Therapeutics is expecting multiple data readouts this year.

2 Stocks That Could Soar This Year: Are They Buys?

Structure Therapeutics Inc

Terns Pharmaceuticals

Wall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss drug market, such as Pfizer, Roche and Amgen.

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

Altimmune

Omega Therapeutics

Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks. Look at obesity drug stocks, like Eli Lilly (NYSE: LLY ) for example.

The 3 Best Biotech Stocks to Buy in January 2024

ExScientia Ltd

ImmunityBio

Two factors –lower interest rates and the low valuation of many biotech stocks — are likely to result in many biotech companies being acquired in 2024. Lower interest rates will result in many drug maker stocks being acquired because cheaper borrowing costs will make it cheaper for firms to borrow the money that they need to finance deals.

M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024

Roche Holding AG

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

Iovance Biotherapeutics

Small to mid-cap biotechs are known for their extreme volatility, and sometimes, market-crushing returns on capital. Iovance Biotherapeutics and Viking Therapeutics are two of the most popular stocks within this group.

Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?

Viking Therapeutics benefitted indirectly from a big-ticket buyout of a peer. Roche could end up paying over $3 billion in that deal.

Why Viking Therapeutics Was Crushing It This Week

VKTX is a biotech company with drugs for obesity and non-alcoholic steatohepatitis (NASH), among others. VKTX has four catalysts on tap in H1'24, with data from the company's weight loss drug, VK2735, looking set to produce data in Q1'24. VKTX has $376M in cash, cash equivalents and short-term investments, meaning the company is funded for years to come.

Viking: Results From 2 Clinical Trials Of Weight Loss Drug Ahead, Other Catalysts On Tap

Late Breaking Poster Presentation Reports New Results Demonstrating Robust Liver Fat Reductions Across Key Subgroups, Including Patients with Type 2 Diabetes and Among Those with F2 or F3 Fibrosis Presentation also Highlights Previously Reported Results Showing Successful Achievement of Study's Primary Endpoint, Statistically Significant Liver Fat Reductions from Baseline to Week 12 Among Patients Receiving VK2809 52-Week Biopsy Results Expected 1H 2024 SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the ongoing Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The latest findings from the VOYAGE study were featured in a late breaking poster presentation at the Liver Meeting® 2023, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), which is being held November 10-14, 2023, in Boston.

Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023

Viking Therapeutics is looking to profit from the expanding market for obesity drugs. The company's two leading candidates are currently in phase 2 clinical trials.

News for Viking Therapeutics Stock (VKTX)